Axsome Therapeutics director Mark Coleman sells $322,473 in stock

Axsome Therapeutics (AXSM) director Mark Coleman sold 3,000 shares at $107.491 amid strong revenue growth; Q1 revenue increased 62% year-over-year to $121.46 million, slightly missing estimates, while EPS exceeded expectations. The company secured a $570 million credit facility from Blackstone to refinance debt and anticipates cash flow positivity early next year. Analysts are maintaining Buy ratings with price target adjustments, reflecting both revenue forecast revisions and confidence in product growth.

Analysis

Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company valued at $5.36 billion, recently saw a director, Mark Coleman, sell 3,000 shares on May 20, 2025, at a weighted average price of $107.491, for a total of approximately $322,473; Coleman retains a substantial holding of 54,137 shares directly and 403,856 shares indirectly. The company has demonstrated significant growth, with revenue increasing 72% over the last twelve months and maintaining impressive gross profit margins exceeding 91%, although InvestingPro notes it is currently trading above its Fair Value. For Q1 2025, Axsome reported a 62% year-over-year revenue increase to $121.46 million, slightly missing the $121.58 million forecast, but exceeded earnings expectations with a loss per share of $1.22, better than the anticipated $1.30 loss. To bolster its financial position, Axsome secured a $570 million credit facility from Blackstone, comprising a $500 million term loan and a $70 million revolving credit facility, which will be used to retire its previous loan with Hercules Capital and potentially reduce interest expenses. With $300.9 million in cash at quarter-end, the company anticipates reaching cash flow positivity early next year. Analyst sentiment remains generally positive, with H.C. Wainwright lowering its price target to $180 (from $200) due to higher operating expenses and revised revenue forecasts, while BofA Securities raised its target to $176, both maintaining Buy ratings, the latter citing strong prescription growth for Auvelity-MDD. Axsome is also advancing its pipeline, with positive Phase 3 trial results for SYMBRAVO, its candidate for migraines, preparing for launch.

Key Decisions for Investors

• Investors should closely monitor Axsome's upcoming revenue figures against forecasts, operating expense management, and progress towards achieving cash flow positivity early next year, particularly given the recent slight revenue miss and analyst concerns over opex.
• Evaluate the sustained prescription growth momentum of Auvelity-MDD and the market reception of the upcoming SYMBRAVO launch, as these are critical drivers for future revenue realization and continued analyst confidence.
• Consider the current valuation, noted by InvestingPro as potentially above Fair Value, alongside the recent insider share sale, when making new investment decisions or adjusting existing positions, despite the company's strong growth metrics and secured financing.